---
anonymous_label: OUT-02
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 023524d63743c863f46cb8e4d661764ff424e1bd28f4f3f3cc813c647042d2e9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-02

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current growth signals are "entangled" and likely artificial. Expansion bookings are driven by temporary pricing bundles rather than perceived value, and usage spikes are being skewed by managers running samples for meetings rather than adjusters using the tool for production. Most critically, you have a "black box" problem: health-liability adjusters are abandoning the tool because they cannot explain its logic to reviewers.

The Usage Quality Sprint tracks *that* people are using the tool, and the Commercial Cleanroom tracks *if* they will pay for it, but neither explains *why* the product is failing in production. The Claim File Review is the only option that provides a qualitative autopsy of the workflow (accepted vs. overridden vs. impossible to explain). This evidence is required to determine if DraftPath needs a fundamental architectural change (explainability) or simply better enablement before you commit next year's budget to scaling a leaky bucket.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the three validation tests. It requires manual effort from adjusters and reviewers, providing a small sample size of deep insight rather than the broad, quantitative data provided by the Usage Quality Sprint or the Commercial Cleanroom.

**Evidence That Would Change My Mind:** If the "wrong recommendation" support tickets (now hidden in training channels) showed a drastic decrease in actual error rates and an increase in "how-to" queries, I would shift to the **Commercial Cleanroom**. This would suggest the product is functionally sound and the primary risk is merely a pricing/packaging misalignment rather than a core utility failure.
